Fig 1: The effects of naringin on hepatic lipogenesis. Hepatic expression of (A) sterol regulatory element binding protein-1c (SREBP-1c), (B) nuclear SREBP-1c (nSREBP-1c), (C) carbohydrate response element-binding protein (ChREBP), (D) fatty acid synthase (FAS), (E) acetyl CoA carboxylase (ACC), (F) glycerol-3-phosphate acyltransferase 1 (GPAT-1) and (G) diacylglycerol/acyl-CoA acyltransferase-2 (DGAT2) in control rats (C), fructose-fed rats (HF), fructose-fed rats treated with naringin at 100 mg/kg (HFN) and control rats treated with naringin at 100 mg/kg (CN). The results are presented as the mean ± standard error of the mean (n = 5 per group). * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control group; + p < 0.05, ++ p < 0.01, +++ p < 0.001 compared with the HF group.
Supplier Page from Abcam for Anti-GPAM antibody